News & Updates
Filter by Specialty:
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022
NAFLD tied to CVD risk even in lean patients
Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.
NAFLD tied to CVD risk even in lean patients
06 Jun 2022
High E/e’ tied to poor prognosis in HFrecEF
In patients with heart failure and recovered ejection fraction (HFrecEF), having a high ratio between the peak velocity of the early wave to early diastole (E/e’) may signal worse clinical prognosis, a recent study has found.